IMPEDIMED LIMITED — AGM Information 2021

Nov 9, 2021

==> picture [230 x 54] intentionally omitted <==

10 November 2021

ASX ANNOUNCEMENT

2021 Annual General Meeting – Chairman’s Address

ImpediMed Limited ( ImpediMed ) (ASX: IPD) provides the attached Chairman’s Address to be delivered at today’s Annual General Meeting commencing at 9.00am AEDT.

The webcast of the AGM can be joined at: www.agmlive.link/IPD21.

Authorised for release by Mr Scott Ward, Chairman of ImpediMed Limited.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: https://www.impedimed.com/products/sozo/.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

10 November 202 1

==> picture [230 x 54] intentionally omitted <==

ImpediMed Limited – 2021 Annual General Meeting Chairman’s Address

So welcome and thank you for joining us today. I hope that all of you and your families are healthy and are continuing to successfully navigate this pandemic.

As I begin my prepared remarks, I would like to extend our gratitude to our customers, who not only continued to serve our patients throughout the corona virus crisis, but also served on the front line caring for patients under very difficult conditions. During these challenging times, we are immensely proud and humbled to partner with such extraordinary physicians and healthcare workers.

As I reflect on this past year, there have been many extraordinary challenges as we have continued to respond and adjust to the impacts of COVID on society, healthcare and our business. Despite these continued COVID headwinds, ImpediMed and its Software-as-a-Service business model has continued to thrive. In FY21, we delivered solid financial performance and achieved our key development milestones, as demonstrated by the recent release of the PREVENT clinical trial results.

The conduct of large scale, hallmark clinical trials is never easy and often requires incredible effort, patience, and perseverance. PREVENT is no different and we are very grateful to our principal investigators and medical advisers for their dedication and commitment to this trial.

As you know, the PREVENT trial achieved its primary endpoint providing Level I medical evidence that screening patients for prospective breast cancer related lymphedema – using bioimpedance spectroscopy – achieves a clinically and statistically significant reduction in chronic lymphedema. This Level I evidence is key to securing reimbursement and establishing our product as the standard of care for patients at risk of developing lymphedema.

Looking ahead, the results of the PREVENT trial and advancements in the SOZO platform put the Company in a strong position for continued growth and success with a highly scalable business model in lymphoedema and important potential new opportunities in heart failure, renal failure and other potential markets.

Our Managing Director and CEO, Richard Carreon, has shown tremendous vision and perseverance in transforming ImpediMed to become a contemporary medical technology company. In addition, we have a strong Board of Directors at ImpediMed with the experience and skill necessary to assure sound governance, while also providing effective support and guidance for Management.

Following a successful capital raise, ImpediMed is now progressing to the next phase of its journey and I believe that the company is well positioned to fulfill its Mission and improve the quality of care for patients around the world.

As a result, after eight years of service, I have determined that this is a good time for me to step aside and allow new leadership to chart the path forward. I will not seek re-election and I will retire from the Company’s Board at the conclusion of today’s annual meeting.

I would like to thank our ImpediMed employees for their dedication and commitment to the patients and customers we serve, and I also thank my fellow Directors for their many contributions to ImpediMed and their ongoing commitment to the Company. Finally, I thank you, our shareholders, for your support over the years and I wish you continued success in the future.

It is now my pleasure to introduce Mr. Donald Williams. The Board has elected Don to be the new Chairman, effective from the conclusion of today’s AGM. Mr Williams was appointed to the Board in 2017, chairs the Remuneration Committee and serves on the Audit and Risk Committee. He has more than 35 years of experience in leadership roles as a Certified Public Accountant and a Public Company Director. I am very pleased that Don has accepted this new role and I am confident that he will provide strong leadership for the ImpediMed Board of Directors.